Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
102.385,45
-0,03%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cumberland Pharmaceutical Inc (CPIX) Cumberland Pharmaceutical Inc (CPIX) Notizie

Cumberland Pharmaceutical Inc

CPIX
2,26
0,01 (0,44%)
01 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/1/202522:40EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
31/12/202401:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/12/202401:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202423:04EDGAR2Form 8-K - Current report
09/12/202422:05PRNUSFDA APPROVES ACETADOTE® sNDA
05/12/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202423:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202423:09EDGAR2Form 8-K - Current report
07/11/202422:05PRNUSCumberland Pharmaceuticals Reports Third Quarter 2024..
06/11/202423:21PRNUSCUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE..
06/11/202423:12EDGAR2Form 8-K - Current report
05/11/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/11/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/11/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/11/202422:05PRNUSNew Study Compares Caldolor® (ibuprofen injection) to..
04/11/202423:15EDGAR2Form 8-K - Current report
31/10/202421:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024..
03/10/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202417:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202400:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/9/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202423:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/8/202423:07EDGAR2Form 8-K - Current report
06/8/202422:05PRNUSCumberland Pharmaceuticals Reports 16% Sequential Revenue..
02/8/202423:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/7/202422:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024..
10/5/202422:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202423:14EDGAR2Form 8-K - Current report
07/5/202422:05PRNUSCumberland Pharmaceuticals Reports First Quarter 2024..
30/4/202422:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024..
02/4/202422:05PRNUSNEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE..
05/3/202423:10EDGAR2Form 8-K - Current report
05/3/202422:05PRNUSCumberland Pharmaceuticals Reports Annual 2023 Financial..
27/2/202422:05PRNUSCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL..
09/2/202423:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
Apertura: 2,22 Min: 2,21 Max: 2,38
Chiusura: 2,25

La tua Cronologia

NASDAQ
CPIX
Cumberland Pharmaceutical
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci